Navigation Links
Upsher-Smith Announces Milestone in Development of CNS Strategy
Date:12/3/2009

MAPLE GROVE, Minn., Dec. 3 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the next phase of its strategic plan for central nervous system (CNS) diseases with USL255 (extended release topiramate), an internally developed program for the management of epilepsy. USL255 is being developed with Upsher-Smith's proprietary formulation technology and will enter a phase III clinical trial in early 2010 for the adjunctive treatment of epilepsy patients with partial onset seizures. USL255 is designed to provide convenient once daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

"Upsher-Smith's goal is to build our leadership position in the CNS field through three complementary strategies including: alliances and co-development agreements; leveraging development of our core competency in formulation development; and actively pursuing licensing and acquisitions," said Mark Evenstad, President of Upsher-Smith.

The USL255 program for epilepsy builds on Upsher-Smith's other CNS program, PRX1 for the symptomatic treatment of Parkinson's disease. PRX1 is a co-development program with Proximagen Neuroscience, a biopharmaceutical company focused on CNS diseases. In July 2008, Upsher-Smith entered into a worldwide licensing agreement covering the development and commercialization of Proximagen's proprietary PRX1 program.

"The clinical development of USL255 and the PRX1 program with Proximagen are in line with Upsher-Smith's vision to become a leader in providing therapies that empower people suffering from CNS diseases to lead healthy, productive lives," said Evenstad. "These two milestones demonstrate our core competencies and commitment to bringing the highest quality pharmaceuticals to patients for more than eight decades."

About Epilepsy and Parkinson's Disease

Epilepsy is a neurological condition that produces seizures affecting a variety of mental and physical functions. Almost three million people in the U.S. have some form of active epilepsy with about 200,000 new cases of epilepsy diagnosed each year.[1] Parkinson's disease is a chronic, progressive neurodegenerative disease that causes impairment in motor function, as well as many non-motor complications throughout the various stages of the disease. As many as 1 million people in the U.S. suffer from Parkinson's disease, with 1 in 100 people over the age of 60 affected. [2]

About Upsher-Smith

Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit www.upsher-smith.com.

Source:

[1]. Epilepsy Foundation. Available at: http://www.epilepsyfoundation.org/about/. Accessed on November 18, 2009

[2]. National Parkinson Foundation. Available at: http://www.parkinson.org/Page.aspx?pid=225. Accessed on November 18, 2009

SOURCE Upsher-Smith Laboratories, Inc.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
2. Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products
3. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
4. Varian, Inc. Announces Form 10-K Filing
5. Jupiter Medical Center Announces New High-Definition MRI System
6. TeamHealth Teleradiology Announces New Contracts in South Carolina and Illinois
7. Cardio Vascular Medical Device Announces Forward Stock Split
8. PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share
9. Clarient Announces CFO Transition Plan
10. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
11. AMT Announces Management Changes in Light of Refocused Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:7/1/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... be broadcast live over the Internet on Thursday, July 27, ... the quarterly results will be made available at 7:30 a.m. ... The live audio webcast can be accessed via Zimmer Biomet,s ... archived for replay following the conference call. ...
(Date:6/30/2017)... Medical (AVACEN) announced the publication of new research in the peer-reviewed ... AVACEN Treatment Method to significantly reduce the widespread pain ... ... ... 200 to 400 million people worldwide according to The National Fibromyalgia ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has ... contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the ... Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... 21, 2017 , ... West Dermatology is pleased to announce the newest addition ... 2017, Ms. Vu will join West Dermatology’s large network of medical and cosmetic dermatology ... cancer , and more. She graduated from the University of Florida College of Medicine ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... bone marrow cancer that progresses rapidly without treatment. Newly diagnosed patients face intense ... chance of reoccurrence and relapse. With such a challenging diagnosis that requires ...
Breaking Medicine News(10 mins):